Activity of Oral ALS-008176 in a RespiratorySyncytial Virus Challenge Study

DeVincenzo JP, McClure MW, Symons JA, Fathi H, Westland C, Chanda S, Lambkin‑Williams R, Smith P, Qingling Zhang Q, Beigelman L, Blatt LM, Fry J.

Nucleoside analogue for RSV
 
ALS-008176 is a potent oral inhibitor of viral replication when administered early after viral challenge of 62 healthy adults. This is the conclusion by DeVincenzo and colleagues from Alios BioPharma and Retroscreen Virology. Treatment was started after confirmation of RSV infection or 6 days after inoculation. Treatment was administered every 12 hours for 5 days. Robust and surprisingly rapid inhibition of viral replication was observed within 12 hours after treatment. No rebound viral replication was observed. Infection-related mucous production was almost fully prevented by ALS-008176. No evidence of toxicity was observed during or after a 5 day treatment. Safety and tolerability of single and multiple doses of ALS-008176 is currently tested in infants with RSV bronchiolitis.

Download File